Meeting
2011 ASCO Annual Meeting
A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors.
Authors
L. E. Strong
Quintessence Biosciences, Inc., Madison, WI
L. E. Strong , J. A. Kink , B. Mei , M. N. Shahan , R. T. Raines
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT00818831
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS146)
Abstract #
TPS146
Poster Bd #
41H
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.
First Author: Gerald Steven Falchook
Poster
2019 ASCO Annual Meeting
Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.
First Author: Timothy A Yap